5-异丙基-4-甲基噻唑-2-胺 | 18193-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-异丙基-4-甲基噻唑-2-胺
• 中文别名: 5-异丙基-4-甲基-1,3-噻唑-2-胺
• 英文名称: 5-isopropyl-4-methyl-thiazol-2-amine
• 英文别名: 2-Amino-4-methyl-5-isopropyl-thiazol；5-Isopropyl-4-methylthiazol-2-amine；4-methyl-5-propan-2-yl-1,3-thiazol-2-amine
• CAS: 18193-59-4
• 化学式: C₇H₁₂N₂S
• 分子量: 156.252
• InChiKey: LRKDQFQWYDHSCY-UHFFFAOYSA-N

物化性质

• 熔点：
  72-73 °C
• 沸点：
  261.1±9.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  5-异丙基-4-甲基噻唑-2-胺 在 吡啶 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 N-[5-Isopropyl-3,4-dimethyl-3H-thiazol-(2Z)-ylidene]-3-nitro-benzenesulfonamide
  参考文献：
  名称：

  Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides

  摘要：

  A random high-throughput screening (HTS) program to discover novel normucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out with MT-4 cells against a nevirapine-resistant virus, HIV-1(IIIB-R). The primary hit, a thiazolidene-benzenesulfonamide derivative, possessed good activity. A systematic modification program examining various substituents at the 3-, 4-, and 5-positions on the thiazole ring afforded compounds with enhanced anti-HIV-1 and reverse transcriptase (RT) inhibitory activities. These results confirm the important role of the substituents at these positions and the thiazolidenebenzenesulfonamide motif as a valuable lead series for the next generation NNRTIs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.08.050
• 作为产物：
  描述：

  顺式-4-甲基-2-戊烯 在 碘 、 2-碘酰基苯甲酸 作用下， 以 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 5-异丙基-4-甲基噻唑-2-胺
  参考文献：
  名称：

  Direct preparation of thiazoles, imidazoles, imidazopyridines and thiazolidines from alkenes

  摘要：

  通过两步酮亚胺化/环化方案，一系列杂环化合物，包括噻唑、咪唑、咪唑并吡啶、噻唑烷和二甲氧基吲哚，已直接从烯烃合成。烯烃起始原料可通过多种不同且成熟的途径轻松获得，并能以优异的产率和区域选择性制备多种杂环化合物。

  DOI：

  10.1039/c1ob06587d

文献信息

• Structure-Activity Relationships of 2-Aminothiazole Derivatives as Inducible Nitric Oxide Synthase Inhibitor
  作者：Shigeo Ueda、Hideo Terauchi、Motoji Kawasaki、Akihiro Yano、Motoharu Ido

  DOI：10.1248/cpb.52.634

  日期：——

  Nitric oxide synthase (NOS) has been divided into two major sub-enzymes, i.e. inducible NOS (iNOS) and constitutive NOS (cNOS). Although nitric oxide (NO) plays an important role as host defense mediator, excessive production of NO by iNOS has been involved in the pathology of many inflammatory diseases. Recently, we reported that the 2-imino-1,3-oxazolidine (1a) weakly inhibits iNOS and that introduction of an alkyl moiety on the oxazolidine ring of 1a enhances the inhibitory activity and selectivity for iNOS. In our search for better iNOS inhibitors, we focused our efforts on the 2-aminothiazole scaffold 3 as it possesses a ring similar to that of 1a. In this study, we evaluated the inhibitory activity of a series of 2-aminothiazole derivatives against both iNOS and neuronal NOS (nNOS). Our results show that introduction of appropriately-sized substituents at the 4- and 5-position of the 2-aminothiazole ring improves the inhibitory activity and selectivity for iNOS. We also found that the selectivity of 5a [5-(1-methyl)ethyl-4-methylthiazol-2-ylamine] and 5b [5-(1,1-dimethyl)ethyl-4-methylthiazol-2-ylamine] for iNOS was similar to that of oxazolidine derivative 1b (4-methyl-5-propyl-2-imino-1,3-oxazolidine) and much higher than that of L-NAME. However, we could not enhance the inhibitory activity against iNOS by introducing an alkyl substituent into the 2-aminothiazole ring as we could in the case of oxazolidine one. On the other hand, introduction of bulky or hydrophilic substituent at any position of the 2-aminothiazole ring remarkably decreased or even abolished the inhibitory activity against NOS.

  一氧化氮合酶（NOS）被分为两种主要的亚酶，即可诱导型一氧化氮合酶（iNOS）和构成型一氧化氮合酶（cNOS）。虽然一氧化氮（NO）在宿主防御中发挥重要作用，但iNOS过量产生NO已涉及许多炎症疾病的病理。最近，我们报告了2-亚氨基-1,3-噁唑烷（1a）对iNOS的抑制作用较弱，并且在1a的噁唑烷环上引入烷基基团可以增强对iNOS的抑制活性和选择性。在寻找更好的iNOS抑制剂时，我们将精力集中在2-氨基噻唑骨架3上，因为它具有类似于1a的环状结构。在本研究中，我们评估了一系列2-氨基噻唑衍生物对iNOS和神经型一氧化氮合酶（nNOS）的抑制活性。结果表明，在2-氨基噻唑环的4位和5位引入适当大小的取代基能显著提高对iNOS的抑制活性和选择性。我们还发现，5a [5-(1-甲基)乙基-4-甲基噻唑-2-胺]和5b [5-(1,1-二甲基)乙基-4-甲基噻唑-2-胺]对iNOS的选择性与噁唑烷衍生物1b（4-甲基-5-丙基-2-亚氨基-1,3-噁唑烷）相似，并且远高于 -NAME。然而，我们未能通过在2-氨基噻唑环上引入烷基取代基来增强对iNOS的抑制活性，正如在噁唑烷的情况下所实现的那样。另一方面，在2-氨基噻唑环的任何位置引入笨重或亲水性取代基显著降低甚至完全消除了对NOS的抑制活性。
• [EN] MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI<br/>[FR] DÉRIVÉS DE MANNOSE UTILES POUR LE TRAITEMENT DE PATHOLOGIES ASSOCIÉES À E. COLI ADHÉRENTS
  申请人：ENTEROME

  公开号：WO2017021549A1

  公开（公告）日：2017-02-09

  The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO-(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X' represents OH or X and X' taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6 )-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO-(C1-C6 )-alkyl, CF3 or COCF3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.

  本发明涉及式(I)的甘露糖衍生物：其中R1代表H、CO-(C1-C6)-烷基或CO-烷基芳基，Y代表单键、CH2、O、NR3、S，A代表O、NH或S，X代表H，X'代表OH或X和X'与它们相连的碳原子形成CO基团，R2代表H、线性或支链(C1-C6)-烷基或CF3，R3代表H、C1-C6烷基、CO-(C1-C6)-烷基、CF3或COCF3，R如权利要求1中所述。式(I)的甘露糖衍生物对治疗与粘附性大肠埃希菌（AEC）存在相关的病理病变有用，特别是炎症性肠病（IBD），如克罗恩病和溃疡性结肠炎；尿路感染，特别是疼痛性膀胱综合征和膀胱炎，更特别是间质性膀胱炎；肠易激综合征；代谢性疾病，如代谢性肥胖、糖尿病、高胆固醇血症；自身免疫性炎症性疾病；以及结直肠癌，特别是结肠癌。
• 咪唑[2,1-b]噻唑衍生物及其制备方法和用途
  申请人：四川大学

  公开号：CN105985356B

  公开（公告）日：2018-06-22

  本发明属于化学医药领域，具体涉及咪唑[2,1‑b]噻唑衍生物及其制备方法和用途。本发明提供了一种咪唑[2,1‑b]噻唑衍生物，其结构如式Ⅰ所示。本发明还提供了上述咪唑[2,1‑b]噻唑衍生物的制备方法和用途。本发明化合物具有优良的活性，与NS3/4A抑制剂、NS5A抑制剂、核苷及非核苷类NS5B抑制剂无交叉耐药性，且与NS3/4A抑制剂、NS5A抑制剂、核苷及非核苷类NS5B抑制剂联合应用时具有协同抗病毒的优点，可以独立的或与利巴韦林、PEG‑干扰素‑α、NS3/4A抑制剂、NS5A抑制剂、核苷及非核苷类NS5B抑制剂中的一种或多种形成药物组合物，用于HCV感染患者的治疗。
• Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase
  申请人：Dang Qun

  公开号：US20070232571A1

  公开（公告）日：2007-10-04

  Novel FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

  化学式为I和X的新型FBPase抑制剂在治疗糖尿病和其他与高血糖有关的疾病中有用。
• Glucocorticoid receptor modulators
  申请人：Dow L. Robert

  公开号：US20070117805A1

  公开（公告）日：2007-05-24

  The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to the diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds.

  本发明提供公式I的非甾体化合物，它们是类固醇受体的选择性调节剂（即激动剂和拮抗剂），具体地，是糖皮质激素受体。本发明还提供含有这些化合物的药物组合物，并使用这些化合物治疗需要糖皮质激素受体激动剂或拮抗剂治疗的动物的方法。糖皮质激素受体调节剂对于肥胖症、糖尿病、炎症等疾病是有用的，如下所述。本发明还提供制备这些化合物的中间体和方法。